<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2024</year>
    <pub-dates>
     <date>2024-12-09</date>
    </pub-dates>
   </dates>
   <doi>10.3389/fmed.2024.1409714</doi>
   <abstract>Background: COVID-19 disease has infected more than 772 million people, leading to 7 million deaths. Although the severe course of COVID-19 can be prevented using appropriate treatments, effective interventions require a thorough research of the genetic factors involved in its pathogenesis. Methods: We conducted a genome-wide association study (GWAS) on 7,124 individuals (comprising 6,400 controls who had mild to moderate COVID-19 and 724 cases with severe COVID-19). The inclusion criteria were acute respiratory distress syndrome (ARDS), acute respiratory failure (ARF) requiring respiratory support, or CT scans indicative of severe COVID-19 infection without any competing diseases. We also developed a polygenic risk score (PRS) model to identify individuals at high risk. Results: We identified two genome-wide significant loci (P-value </abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/4730</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/4906</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
